[go: up one dir, main page]

SG10201703678TA - Antibodies to s. aureus surface determinants - Google Patents

Antibodies to s. aureus surface determinants

Info

Publication number
SG10201703678TA
SG10201703678TA SG10201703678TA SG10201703678TA SG10201703678TA SG 10201703678T A SG10201703678T A SG 10201703678TA SG 10201703678T A SG10201703678T A SG 10201703678TA SG 10201703678T A SG10201703678T A SG 10201703678TA SG 10201703678T A SG10201703678T A SG 10201703678TA
Authority
SG
Singapore
Prior art keywords
antibodies
surface determinants
aureus surface
aureus
determinants
Prior art date
Application number
SG10201703678TA
Inventor
Bret Sellman
Christine Tkaczyk
Partha Chowdhury
Lei Hua
Peter Pavlik
Rebecca Buonpane
Chew-Shun Chang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG10201703678TA publication Critical patent/SG10201703678TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201703678TA 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants SG10201703678TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US201361782405P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201703678TA true SG10201703678TA (en) 2017-06-29

Family

ID=50685304

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201503232TA SG11201503232TA (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants
SG10201703678TA SG10201703678TA (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201503232TA SG11201503232TA (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Country Status (17)

Country Link
US (3) US9879070B2 (en)
EP (2) EP3640338A1 (en)
JP (2) JP6694269B2 (en)
KR (1) KR102288394B1 (en)
CN (2) CN109553681A (en)
AU (2) AU2013341361A1 (en)
BR (1) BR112015010125A2 (en)
CA (1) CA2890427C (en)
DK (1) DK2917360T3 (en)
ES (1) ES2776179T3 (en)
HK (2) HK1215054A1 (en)
HU (1) HUE049012T2 (en)
MX (2) MX375324B (en)
PL (1) PL2917360T3 (en)
RU (1) RU2698131C2 (en)
SG (2) SG11201503232TA (en)
WO (1) WO2014074540A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192212A1 (en) 2011-02-08 2013-09-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
ES2859323T3 (en) * 2011-11-07 2021-10-01 Medimmune Ltd Combination therapies using Pseudomonas anti-Psl and PcrV binding molecules
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
ES2912267T3 (en) 2012-11-06 2022-05-25 Medimmune Llc Treatment methods for diseases associated with S. aureus
WO2014074540A2 (en) * 2012-11-06 2014-05-15 Medimmune, Llc Antibodies to s. aureus surface determinants
MX394895B (en) * 2014-06-03 2025-03-24 Xbiotech Inc COMPOSITIONS USEFUL FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS.
TWI719938B (en) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 Treatment of polybacterial infections
CA2956429A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (en) * 2015-03-06 2016-09-09 Commissariat Energie Atomique METHOD AND DEVICE FOR REAL-TIME DETECTION OF A SECRETED COMPOUND AND THE SECRETORY TARGET AND USES THEREOF
CA2978855A1 (en) * 2015-04-17 2016-10-20 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
CN105424930A (en) * 2015-11-23 2016-03-23 天津科技大学 Method for rapidly detecting staphylococcus aureus
CN111148758B (en) * 2017-09-29 2022-12-09 瑞泽恩制药公司 Bispecific antigen binding molecules that bind to staphylococcal target antigens and complement components and uses thereof
JP7525471B2 (en) * 2018-07-24 2024-07-30 メディミューン，エルエルシー Antibodies to S. aureus clumping factor A (ClfA)
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
US11168133B2 (en) 2018-10-09 2021-11-09 Medimmune, Llc Combinations of anti-Staphylococcus aureus antibodies
TW202100549A (en) 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 Decreasing staphylococcus aureus infections in colonized patients
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (en) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 Antibodies against alpha-hemolysin and uses thereof
KR102397684B1 (en) * 2019-12-09 2022-05-13 (주)옵토레인 Peptides binding to antibodies and analyzing method using the same
KR102504175B1 (en) * 2020-06-17 2023-02-28 (주)옵토레인 Peptides binding to antibodies, drug complex, biosensor and analyzing method using the same
KR102674109B1 (en) * 2021-01-14 2024-06-12 (주)옵토레인 Switching peptides, immunoassay apparatus having the switching peptide, and immunoassay method using the switching peptides
KR102674098B1 (en) * 2021-01-14 2024-06-12 (주)옵토레인 Switching peptides and multiplex immunoassay method using the switching peptides
KR102674120B1 (en) * 2021-01-18 2024-06-12 (주)옵토레인 Switching peptides and immunoassay method using the switching peptides

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (en) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
CN101928343B (en) * 2001-01-26 2014-09-17 英希比泰克斯公司 Monoclonal antibodies to the CLFA protein and method of use in treating or preventing infections
JP2007522096A (en) * 2003-06-06 2007-08-09 メディミューン，インコーポレーテッド Use of EphA4 and EphA4 modulators for cancer diagnosis, treatment, and prevention
CA2535171A1 (en) 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
EP1807451A2 (en) 2004-08-03 2007-07-18 Dyax Corporation Hk1-binding proteins
US20080050361A1 (en) 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
US20100040606A1 (en) 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007259415B2 (en) * 2006-06-12 2013-09-26 Glaxosmithkline Biologicals Sa Use of alpha-toxin for treating and preventing Staphylococcus infections
WO2008152447A2 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
WO2009095453A1 (en) * 2008-01-31 2009-08-06 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Treatment of microbial infections
AU2009246510B2 (en) * 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
US8280643B2 (en) * 2008-06-30 2012-10-02 The Texas A & M University System Crystal structure of Staphylococcus aureus clumping factor A in complex with fibrinogen derived peptide and uses thereof
US20110262477A1 (en) * 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
US20120128673A1 (en) * 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
DK2445522T3 (en) * 2009-06-22 2017-09-25 Wyeth Llc IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
SG177653A1 (en) * 2009-07-15 2012-02-28 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US8808699B2 (en) * 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
SG192212A1 (en) * 2011-02-08 2013-09-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
JP6317670B2 (en) * 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Compositions and methods related to antibodies to staphylococcal protein A
RS60499B1 (en) * 2011-12-20 2020-08-31 Medimmune Llc Modified polypeptides for bispecific antibody scaffolds
AU2013252883B2 (en) * 2012-04-26 2018-05-17 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2014074540A2 (en) * 2012-11-06 2014-05-15 Medimmune, Llc Antibodies to s. aureus surface determinants
ES2912267T3 (en) * 2012-11-06 2022-05-25 Medimmune Llc Treatment methods for diseases associated with S. aureus
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EP3057988A2 (en) * 2013-10-15 2016-08-24 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
US20170023569A1 (en) * 2014-01-10 2017-01-26 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
EP3096788B1 (en) * 2014-01-24 2019-07-31 Church, William, R. Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
MX394895B (en) * 2014-06-03 2025-03-24 Xbiotech Inc COMPOSITIONS USEFUL FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS.
TWI719938B (en) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 Treatment of polybacterial infections
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
CA2978855A1 (en) 2015-04-17 2016-10-20 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
WO2018009604A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
JP7525471B2 (en) * 2018-07-24 2024-07-30 メディミューン，エルエルシー Antibodies to S. aureus clumping factor A (ClfA)
WO2020076790A1 (en) * 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
US11168133B2 (en) * 2018-10-09 2021-11-09 Medimmune, Llc Combinations of anti-Staphylococcus aureus antibodies
TW202100549A (en) * 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 Decreasing staphylococcus aureus infections in colonized patients

Also Published As

Publication number Publication date
CA2890427C (en) 2022-05-31
EP3640338A1 (en) 2020-04-22
RU2019122610A (en) 2020-02-18
HK1215054A1 (en) 2016-08-12
MX2015005477A (en) 2015-11-30
BR112015010125A2 (en) 2017-08-22
HK1215452A1 (en) 2016-08-26
EP2917360A4 (en) 2017-01-25
US9879070B2 (en) 2018-01-30
AU2018241107B2 (en) 2020-09-17
KR102288394B1 (en) 2021-08-09
MX375324B (en) 2025-03-06
US20190016787A1 (en) 2019-01-17
US11447543B2 (en) 2022-09-20
CN104968797A (en) 2015-10-07
EP2917360A2 (en) 2015-09-16
MX2022008079A (en) 2022-07-11
CN109553681A (en) 2019-04-02
PL2917360T3 (en) 2020-06-29
US20150291685A1 (en) 2015-10-15
RU2015121624A (en) 2016-12-27
DK2917360T3 (en) 2020-03-30
WO2014074540A3 (en) 2014-07-10
JP6694269B2 (en) 2020-05-13
AU2018241107A1 (en) 2018-10-25
US10730934B2 (en) 2020-08-04
CN104968797B (en) 2018-11-30
JP2016507470A (en) 2016-03-10
JP2019089801A (en) 2019-06-13
RU2698131C2 (en) 2019-08-22
ES2776179T3 (en) 2020-07-29
US20200407429A1 (en) 2020-12-31
WO2014074540A2 (en) 2014-05-15
AU2013341361A1 (en) 2015-06-04
HUE049012T2 (en) 2020-09-28
SG11201503232TA (en) 2015-05-28
EP2917360B1 (en) 2020-01-08
CA2890427A1 (en) 2014-05-15
KR20150094621A (en) 2015-08-19

Similar Documents

Publication Publication Date Title
HK1215452A1 (en) Antibodies to s. aureus surface determinants
IL271697A (en) Anti-cxcr3 antibodies
IL235807A0 (en) Immunoconjugates comprising anti-cd79b antibodies
IL235042A0 (en) Anti-fcrn antibodies
HK1204571A1 (en) Protease-regulated antibodies
IL235989A0 (en) Immunoconjugates comprising anti-cd79b antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
IL235059A0 (en) Anti-il-23p19 antibodies
HK1210186A1 (en) Anti-h7cr antibodies h7cr
ZA201408213B (en) Anti-transglutaminase 2 antibodies
GB201217868D0 (en) Staphyolococcus aureus antigens
IL235188A0 (en) Anti-pdgf-c antibodies